Furthermore, APP/PS1 mice models carrying an APQ4 genetic deletion (AQP4−) demonstrated CAA and augmented build-up of Aβ, leading to the postulation of the attenuating impact of AQP4 in relation to Aβ and this as a promising potential target in future AD therapeutic intervention [47]. The gene discussed is APP; the disease is Alzheimer disease.